Sundeep Bojedla, DO
Neurology · Lakeland, FLNPI 1184043051
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 118 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations.
Across 118 payments — averaging $21.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$342
- Pfizer$262
- GE HealthCare$175
- Eisai Inc.$146
- Lilly USA, LLC$104
- Jazz Pharmaceuticals Inc.$101
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,570100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 26 | $342 |
| Pfizer | 16 | $262 |
| GE HealthCare | 6 | $175 |
| Eisai Inc. | 4 | $146 |
| Lilly USA, LLC | 5 | $104 |
| Jazz Pharmaceuticals Inc. | 4 | $101 |
| Bristol Myers Squibb | 4 | $100 |
| SK Life Science, Inc. | 3 | $98 |
| Acadia Pharmaceuticals Inc | 4 | $93 |
| Neurelis, Inc. | 4 | $92 |
| Axsome Therapeutics, Inc. | 3 | $90 |
| Argenx US, Inc. | 3 | $82 |
| Novo Nordisk | 4 | $82 |
| Tanabe Pharma America, Inc. | 3 | $71 |
| CSL Behring | 2 | $63 |
| Neurocrine Biosciences, Inc. | 2 | $62 |
| Otsuka America Pharmaceutical, Inc. | 3 | $62 |
| Genentech USA, Inc. | 2 | $60 |
| Teva Pharmaceuticals USA, Inc. | 2 | $58 |
| Vanda Pharmaceuticals Inc. | 2 | $56 |
| Catalyst Pharmaceuticals, Inc. | 2 | $54 |
| UCB, Inc. | 2 | $41 |
| Lundbeck LLC | 2 | $39 |
| TG Therapeutics, Inc. | 1 | $37 |
| Novartis | 2 | $36 |
| AstraZeneca | 1 | $31 |
| Johnson & Johnson | 1 | $28 |
| Boston Scientific | 1 | $27 |
| MDD US Operations, LLC | 1 | $24 |
| Grifols USA, LLC | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $20 |
| Aucta Pharmaceuticals, Inc. | 1 | $14 |
How this compares
$2,570 in reported general payments places this provider in the 55th percentile of 1,434 neurology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 117 | $2,611 |
| Memantine Hcl | 68 | $1,743 |
| Levetiracetam | 37 | $1,512 |
| Donepezil Hcl | 99 | $1,471 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 47 | $1,447 |
| Galantamine ErGalantamine Hbr | 13 | $1,371 |
| Pregabalin | 48 | $1,286 |
| Quetiapine Fumarate | 16 | $1,110 |
| Oxcarbazepine | 21 | $1,090 |
| Primidone | 31 | $875 |
| Duloxetine Hcl | 28 | $690 |
| Propranolol Hcl ErPropranolol Hcl | 12 | $688 |
| Baclofen | 35 | $603 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 37 | $591 |
| Ropinirole Hcl | 11 | $515 |
Paid to pharmacies, not to this prescriber.
Other neurology in Lakeland
- Stuart IsaacsonBoca Raton$3.9M
- Selim BenbadisTampa$2.1M
- Derrick RobertsonTampa$1.8M
- Robert HauserTampa$1.6M
- David RoseTampa$1.4M
- Matthew BakerNaples$1.4M
- Donald NegroskiSarasota$1.4M
- Mark CascioneTampa$1.2M
- Lance KimOcala$1M
- Tuan VuTampa$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.